Potentiation of the antidepressant-like effect of desipramine or reboxetine by metyrapone in the forced swimming test in rats

Baez M, Volosin M: Corticosterone influences forced swim-induced immobility. Pharmacol Biochem Behav 1994, 49, 729–736. Bschor T, Canata B, Muller-Oerlinghausen B, Bauer M: Predictors of response to lithium augmentation in tricyclic antidepressant-resistant depression. J Affect Disord 2001, 64, 261–265. Chalmers DT, Kwak SP, Mansour A, Akil H, Watson SJ: Corticosteroids regulate brain hippocampal 5-HT1A receptor mRNA expression. Trends Neurosci 1993, 13, 914–923. Forster EA, Cliffe IA, Bill DJ, Dover GM, Jones D, Reilly Y, Fletcher A: A pharmacological profile of the selective silent 5-HT1A receptor antagonist, WAY 100635. Eur J Pharmacol 1995, 281, 81–88. Goodwin GM, DeSouza RJ, Green AR: Attenuation by electroconvulsive shock and antidepressant drugs of the 5-HT1A receptor-mediated hypothermia and serotonin syndrome produced by 8-OH-DPAT in the rat. Psychopharmacology (Berl) 1987, 91, 500–505. Healy DG, Harkin A, Cryan JF, Kelly JP, Leonard BE: Metyrapone displays antidepressant-like properties in preclinical paradigms. Psychopharmacology (Berl) 1999, 145, 203–208. Heuser IJE, Schweiger U, Gotthardt U, Schmider J, Lammers CH, Dettling M, Yassouridis A, Holsboer F: Pituitary-adrenal-system regulation and psychopathology during amitriptyline treatment in elderly depressed patients and normal comparison subjects. Am J Psychiatry 1996, 153, 93–99. Holsboer F: The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology 2000, 23, 477–501. Holsboer F, Barden N: Antidepressants and hypothalamic-pituitary-adrenocortical regulation. Endocr Rev 1996, 17, 187–205. Holsboer F, Gerken A, Stella GK, Muller O: ACTH, Cortisol and corticosterone output after ovine corticotrophin-releasing factor challenge during depression and after recovery. Biol Psychiatry 1985, 20, 276–286. Jahn H, Schick M, Kiefer F, Kellner M, Yassouridias A, Wiedemann K: Metyrapone as additive treatment in major depression: a double-blind and placebo-controlled trial. Arch Gen Psychiatry 2004, 61, 1235–1244. Janssen PAJ, Jageneau AHM, Schellekens KHL: Chemistry and pharmacology of compounds releated to 4-(4-hydroxy-4-phenyl-piperidino)-butyrophenone. Part IV. Influence of haloperidol (R 1625) or chloropromazine on the behaviour of rats in unfamiliar “open field” situation. Psychopharmacologia 1960, 1, 389–392. Jeffcoate WJ, Silverstone JT, Edwards CR, Besser GM: Psychiatric manifestations of Cushing’s syndrome: response to lowering of plasma Cortisol. Q J Med 1979, 48, 465–472. Kennett GA, Dickinson SL, Curzon G: Central serotonergic responses and behavioral adaptation to repeated immobilization: the effect of the corticosterone synthesis inhibitor metyrapone. Eur J Pharmacol 1985, 119, 143–152. Korstein SG, Schneider RK: Clinical features of treatment-resistant depression. J Clin Psychiatry 2001, 62, Suppl 16, 18–25. Linkowski P, Mendlewicz J, Leclercq R, Brasseur M, Hubain P, Goldstein J, Copinschi G, Van Cauter E: The 24-hour profile of adrenocorticotropin and Cortisol in major depressive illness. J Clin Endocrinol Metab 1985, 61, 429–438. Majewska MD: Neurosteroids: endogenous bimodal modulators of the GABAA receptor. Mechanism of action and physiological significance. Prog Neurobiol 1992, 38, 379–395. Murphy BEP: Antiglucocorticoid therapies in major depression: a review. Psychoendocrinology 1997, 22, Suppl 1, S125–S132. Nemeroff CB, Widerlöv E, Bissette G, Walléus H, Karlsson I, Eklund K, Kilts CD et al.: Elevated concentrations of CRF corticotropin releasing factor-like immunoreactivity in depressed patients. Science 1984, 226, 1342–1344. O’Brien D, Skelton KH, Owens MJ, Nemeroff CB: Are CRF receptor antagonists potential antidepressants? Hum Psychopharmacol, 2001, 16, 81–87. Pariante CM, Miller AH: Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment. Biol Psychiatry 2001, 49, 391–404. Porsolt RD, Anton G, Blavet N, Jalfre M: Behavioural despair in rats, a new model sensitive to antidepressant treatment. Eur J Pharmacol 1978, 47, 379–391. Price LH, Malison RT, McDougle CJ, Pelton GH: Antiglucocorticoids as treatments for depression. Rationale for use and therapeutic potential. CNS Drugs 1996, 5, 311–320. Raven PW, O’Dwyer A-M, Taylor NF, Checkley SA: The relationship between the effect of metyrapone treatment on depressed mood and urinary steroid profiles. Psychoneuroendocrinology 1996, 21, 277–286. Rogóż Z: Effect of repeated co-treatment with Imipramine and metyrapone on the behavioral reactivity of the central serotonin, dopamine and α1-adrenergic system in rats. Pharmacol Rep 2007, 59, 588–594. Rogóż Z, Budziszewska B, Kubera M, Basta-Kaim A, Jaworska-Feil L, Skuza G, Lasoń W: Effects of combined treatment with imipramine and metyrapone on the immobility time, the activity of hypothalamo-pituitary-adrenocortical axis and immunological parameters in the forced swimming test in the rat. J Physiol Pharmacol 2005, 56, 49–61. Rogóż Z, Skuza G, Leśkiewicz M, Budziszewska B: Effects of co-administration of fluoxetine or tianeptine with metyrapone on immobility time and plasma corticosterone concentration in rats subjected to the forced swim test. Pharmacol Rep 2008, 60, 880–888. Rogóż Z, Skuza G, Wójcikowski J, Daniel WA: Effect of combined treatment with imipramine and metyrapone in the forced swimming test in rats. Behavioral and pharmacokinetic studies. Pol J Pharmacol 2003, 55, 993–999. Rogóż Z, Skuza G, Wójcikowski J, Daniel WA, Wróbel A, Dudek D, Zięba A: Effect of metyrapone supplementation on imipramine therapy in patients with treatment-resistant unipolar depression. Pol J Pharmacol 2004, 56, 849–855. Roozendaal B, Bohus B, McGaugh JL: Dose-dependent suppression of adrenocortical activity with metyrapone: effects on emotional and memory. Psychoendocrinology 1996, 21, 681–693.